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INTRODUCTION
RADIOACTIVE iodine (iodine-131) has been used extensively during the past 30
years for the treatment of hyperthyroidism and has been shown to control this
disorder in the majority of cases in which it has been used. There have been
varying reports of the incidence of post-radiation hypothyroidism which has been
reported to be as high as 70 per cent in patients followed up for 10 years (Beling
and Einhorn, 1961; Dunn and Chapman, 1964; Nofal, Beierwaltes and Patno,
1966; Green and Wilson, 1969). In recent years smaller doses of iodine-131 have
been used to try to minimise this complication (Smith and Wilson, 1967; Hagen,
Ouellette and Chapman, 1967; Hagen, 1968; Smith, Munro and Wilson, 1970,
Blahd and Hays, 1972; Rapoport, Caplan and De Groot, 1975).
The experience of this unit with conventional doses of iodine-131 (using
approximately 150 ,uCi per gram thyroid tissue) has been reported (Bhatia,
Hadden, Montgomery and Weaver, 1968). Since then we have prescribed lower
doses of approximately 70 uCi per gram of thyroid tissue, and from 1970 doses of
approximately 35 1ACi per gram. We have used these two doses rather than a dose
calculated from neck uptake data. Furthermore, these doses could be given to
outpatients without the need for inpatient supervision and disposal of excretory
products.
The purpose of this paper is to report our experience using these smaller doses
of radioactive iodine in the management of patients with hyperthyroidism.
PATIENTS AND METHODS
Patients were referred to the Metabolic Unit of the Royal Victoria Hospital
from all parts of Northern Ireland between 1968 and 1973. The diagnosis of
hyperthyroidism was made on the clinical findings and the standard biochemical
tests then available (protein bound iodine, T3 red cell uptake and serum choles-
terol). Iodine-131 neck uptake studies were often performed for diagnostic
purposes prior to therapy. The size of the thyroid gland was estimated by
palpation. Iodine-131 was not given to patients under 40 years of age.
Before 1964, doses of iodine-131 calculated to deliver 6000 to 8000 rads to the
thyroid, or 150 ptCi per gram of thyroid tissue were used in the Metabolic Unit
(Bhatia et al, 1968). Doses in the region of 8.5 mCi were used until 1964 when the
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2.5 mCi was given routinely to those patients where radioactive iodine was
indicated. In 1970 a smaller standard dose of 1.25 mCi was introduced. From 1968
propranolol, 160 mg per day in divided doses, was given until the iodine-131 had
taken effect (Hadden, Montgomery, Shanks and Weaver, 1968). Although a
random allocation to treatment with 2.5 or 1.25 mCi was not followed, we do not
believe that there was any real clinical or biochemical difference between the two
groups (Tables 1 and 2). One hundred and seventeen patients received 2.5 mCi
Table 1
Comparison of ages and thyroid size in two dosage groups
Mean age Mean thyroid size (g)
(years) + SD + SD
2.5 mCi Patients remaining euthyroid 52.3 ± 10.7 33 + 10
doses (at least 5 years)
Patients now hypothyroid 49.8 ± 8.7 30 ± 7
1.25 mCi Patients remaining euthyroid 51.3 + 8.4 32 + 10
doses (at least 5 years)
Patients now hypothyroid 48.1 ± 10.3 35 ± 5
Table 2
Relative degree of thyroid overactivity at first treatment
Euthyroid (at least S years) Now hypothyroid
No. ofpatients Mean PBI ± SD No. ofpatients Mean PBI ± SD
1.25 mCi doses
Singledose 22 11.4 2.4 2 11.8 2.9
2 doses 10 11.7 2.1 2 11.4 1.8
3 doses 4 13.3 2.2 1 10.0
2.5 mCi doses
Single dose 24 11.7 ± 2.2 30 11.1 ± 2.5
2nd dose(1.25 mCi) 1 14.8 2 13.0
2nd dose (2.5 mCi) 8 9.9 ± 1.6 7 12.5 ± 0.9
iodine-131 and 77 of this group have been followed up for at least seven years.
Seventy-one patients were treated with 1.25 mCi and 24 have been followed up for
at least seven years. A number of patients treated with 2.5 mCi doses have been
followed up for 10 years and a few of those treated with 1.25 mCi doses have
been followed up for eight years, but the numbers become too small to make valid
72comparisons. Patients remaining biochemically hyperthyroid after three to four
months received a further dose of radioactive iodine and a number of patients
required multiple doses (Tables 3 and 4).
Table 3
1.25 mCi doses (71 patie:
Total dose No. of
(mCi) patients
treated
Single dose 1.25 28
2 doses 2.5 17
3 doses 3.75 11
More than 3 doses 15
(mean 7.4 +±3.1)
Table 4
nts) 2.5 mCi doses (117 patients)
Per cent Total dose No. of Per cent
(mCi) patients
39.4
23.9
15.5
21.1
treated
Single dose 2.5 79
2 doses 3.75 3
2 doses 5.0 16
3 doses 6.25 2
3 doses 7.5 10
More than 3 doses 7
(mean 12.1 ± 2.4)
67.5
2.6
13.7
1.7
8.5
6.0
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FIG. 1 Cumulative incidence of hypothyroidism followng 2.5 mCi and 1.25 mCi doses of
iodine-131. Results of single and multiple doses shown separately.
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HYPOTHYROIDThe diagnosis of hypothyroidism was made on the clinical features together
with a PBI of less than 3.5 pug/100 ml or T3 red cell uptake of less than 10 per
cent. In recent years serum T4, T3 and TSH values by radioimmuniassay have been
in use and the diagnosis confirmed by low T4 and T3 levels with an elevated TSH.
The cumulative incidence of hypothyroidism was calculated by the life-table
method (Berkson and Gage, 1950; Cutler and Ederer, 1958) which provides a
corrective factor for patients lost to follow up.
RESULTS
Figure 1 shows the results of the two dosage regimes. Because the number of
patients followed up between eight and ten years are relatively small, a comparison
of the incidence of hypothyroidism in the two groups has been made at seven
years.
I
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4'
Bhatia et al
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FIG. 2 Comparison of results with 2.5 mCi and 1.25 mCi doses of
of Bhatia et al (1968). .....
Our experience with higher doses of iodine-131 (Bhatia et
years is shown for comparison (Fig 2).
iodine-131 with results
al, 1968) up to six
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were hypothyroid, and of those followed up for ten years, 51.3 per cent were
hypothyroid. Patients receiving multiple doses of 2.5 mCi (mean dose 6.9 + 2.9)
showed a cumulative incidence of hypothyroidism of 36.4 per cent at seven years,
which did not increase at ten years.
At seven years 11.7 per cent of patients treated with a single dose of 1.25 mCi
were hypothyroid, and of those patients followed up to eight years no more
became hypothyroid. Hypothyroidism occurred in 17.4 per cent of those receiving
multiple doses of 1.25 mCi (means 4.5 ± 2.8) and there was no increase at eight
years.
The mean duration of biochemical hyperthyroidism following first treatment
was 6.8 ± 7.7 months in the 2.5 mCi dose group and 8.5 + 8.8 months in the 1.25
mCi dose group. Thirteen patients treated with 2.5 mCi doses were lost to follow
up before five years and two patients died of causes unrelated to their hyperthy-
roidism. Five patients treated with 1.25 mCi doses were lost to review before five
years and five patients died.
Two patients treated initially with 1.25 mCi remain on long term antithyroid
drug treatment with carbimazole. One case was resistant to multiple doses
totalling 15.0 mCi while the other case, treated with two doses of 1.25 mCi is now
euthyroid. There were four cases of late relapse of hyperthyroidism (after three
years) in the 1.25 mCi group. These patients were treated with further doses of
iodine-131. One patient first treated with a 2.5 mCi of iodine-131 remains on
carbimazole following relapse of hyperthyroidism at five years and multiple doses
totalling 12.5 mCi. There was one other late relapse at six years in the 2.5 mCi
group.
At the most recent review no patient remained hyperthyroid.
DISCUSSION
There is great variability in the reported incident of post-radiation hypo-
thyroidism. The difficulties in analysing data which involves variations in length
of follow up can be minimised by using the lifetable method. Glennon et al, 1972
have compared several previous studies using this method and their results are
shown in Fig. 3.
Figures 1 and 2 show that the annual incidence of hypothyroidism can be
substantially reduced by the use of lower doses of iodine-131. The difference in
incidence of hypothyroidism between the two low dosage groups at seven years
was significant (p<0.05), with the proviso that the statistics were done on retro-
spective data and the treatments were not strictly randomised. No statistics were
possible on the data of Bhatia et al for comparison. The argument against low
dose iodine-131 therapy is that patients may remain hyperthyroid longer until the
iodine-131 has taken effect, and that the patients will be subjected to repeated
treatments and frequent attendance at outpatient clinics. However, the mean
period of biochemical hyperthyroidism did not differ greatly in the two dosage
groups studied, although the number of retreatments was greater in the 1.25 mCi
dose group.
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FIG. 3 Taken from Glennon et al (1972). Solid lines indicate data originally reported
using the life-table method; broken lines indicate data recalculated from the
reported data using the life-table method.
Individual sensitivity to radioiodine is a possible factor in the development of
hypothyroidism. No difference in age or size of the thyroid was observed in those
patients requiring multiple doses nor was there any apparent difference in the
degree of thyroid overactivity at first treatment in patients requiring single or
multiple doses, or in those becoming hypothyroid.
These findings differ from the recent reports from the USA of a six year
incident of hypothyroidism of 10 to 25 per cent following doses of 3 to 4 mCi
(Cevallos et al, 1974; Glennon et al, 1972). It may be that the natural history of
hyperthyroidism differs in different communities and that autoimmunity may be a
factor in the ultimate development of hypothyroidism in patients treated with
iodine-131.
Our policy of restricting iodine-131 treatment to patients over the age of 40
years may have contributed to the apparent high incidence of hypothyroidism at
review compared with the results of American workers. Green and Wilson (1964)
reported a lower incident of hypothyroidism in patients under 40 years of age, but
attributed this to a larger thyroid gland in those younger patients treated. Bhatia
et al (1968) found a higher incidence of hypothyroidism in patients aged 40 to 49
years compared with patients over 60. No definite trend was observed in the
present series.
76We have shown a difference in the results of treatment with two low dose
regimens and compared this with our previous experience of more conventional
doses of iodine-131 in this community. The lower incident of permanent hypo-
thyroidism is offset by the need for repeated treatments in the 1.25 mCi group.
As our patients are kept under regular review, it may be better to accept a higher
rate of hypothyroidism, as this can be easily treated, and avoid frequent retreat-
ments. Accordingly, we continue to use 2.5 mCi as a routine dose and retain the
lower dose for milder cases.
SUMMARY
The cumulative incidence of hypothyroidism after therapeutic radioiodine for
hyperthyroidism in patients over 40 years was 38 per cent seven years after a single
dose of 2.5 mCi iodine-131, and 12 per cent seven years after a single dose of 1.25
mCi.
Thirty-three per cent of patients treated with 2.5 mCi required further doses,
compared to 60 per cent of patients treated with 1.25 mCi. Where close supervision
and outpatient follow up can be attained, the use of low dose radioiodine therapy
can result in a much lower incidence of post-radiation hypothyroidism.
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GASTROINTESTINAL ENDOSCOPY. AN INTRODUCTION FOR ASSIST-
ANTS. D. Hollanders. (Pp 168; figs 49. £4.75). London: Bailliere Tindall, 1979.
IT is now over forty years since Mr. Harold W. Rogers, assisted by Dr. Francis Avery
Jones, passed the first semiflexible gastroscope at St. Bartholomew's Hospital. Today fibre-
optic endoscopy plays a key role in the investigation and management of digestive disease.
The instrumentation is now widely available and if it is to continue to be widely avail-
able as resources contract emphasis must be placed on careful handling of the equipment
by well-informed assistants and endoscopists.
There are now many texts dealing with the techniques and interpretation of gastro-
intestinal endoscopic procedures but few are of practical value to the nurse or radio-
grapher designated to assist in their performance. This small text fills a gap in the British
Literature by giving all of the necessary informttion with which an assistant should be
familiar. Subjects such as physical principles, equipment design and medication for endos-
copy are well presented without too much technical detail.
The most useful chapters deal with the assistant's role both in the care of the patient
and in the care of the equipment. Since these instruments are both fragile and expensive
care to detail in their cleaning and handling is essential if expensive repairs and shortened
instrument life are to be avoided. This book should be available in endoscopy units as an
introduction for the trainee endoscopist and trainee assistant alike.
R.J.McF.
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